During the recent session, TScan Therapeutics Inc. (NASDAQ:TCRX)’s traded shares were 1.34 million. At the last check today, the stock’s price was $2.36, reflecting an intraday loss of -2.88% or -$0.07. The 52-week high for the TCRX share is $6.03, that puts it down -155.51 from that peak though still a striking 38.56% gain since the share price plummeted to a 52-week low of $1.45. The company’s market capitalization is $60.36M, and the average intraday trading volume over the past 10 days was 0.61 million shares, and the average trade volume was 1.35 million shares over the past three months.

TScan Therapeutics Inc. (TCRX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. TCRX has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.75.

TScan Therapeutics Inc. (NASDAQ:TCRX) trade information

TScan Therapeutics Inc. (TCRX) registered a -2.88% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.88% in intraday trading to $2.36 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -26.25%, and it has moved by 7.88% in 30 days. Based on these gigs, the overall price performance for the year is -18.06%. The short interest in TScan Therapeutics Inc. (NASDAQ:TCRX) is 89600.0 shares and it means that shorts have 4.51 day(s) to cover.

The consensus price target of analysts on Wall Street is $10.50, which implies an increase of 77.52% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6.00 and $15.00 respectively. As a result, TCRX is trading at a discount of -535.59% off the target high and -154.24% off the low.

TScan Therapeutics Inc. (TCRX) estimates and forecasts

Statistics show that TScan Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. TScan Therapeutics Inc. (TCRX) shares have gone up 5.83% during the last six months, with a year-to-date growth rate less than the industry average at -3.27% against 11.70. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -19.00% this quarter and then drop -50.70% in the quarter after that. In the rating firms’ projections, revenue will increase 135.60% compared to the previous financial year.

Revenue for the current quarter is expected to be $13.54 million as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $3.62 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $4.06 million and $3.7 million respectively. In this case, analysts expect current quarter sales to grow by 233.80% and then drop by -2.20% in the coming quarter.

While earnings are projected to return -33.60% in 2023.

TCRX Dividends

TScan Therapeutics Inc. is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

TScan Therapeutics Inc. (NASDAQ:TCRX)’s Major holders

TScan Therapeutics Inc. insiders own 6.91% of total outstanding shares while institutional holders control 64.28%, with the float percentage being 69.05%. Baker Brothers Advisors, LLC is the largest shareholder of the company, while 39 institutions own stock in it. As of Mar 30, 2023, the company held over 2.78 million shares (or 14.30% of all shares), a total value of $5.85 million in shares.

The next largest institutional holding, with 1.52 million shares, is of Blackrock Inc.’s that is approximately 7.78% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $3.18 million.

Also, the Mutual Funds coming in first place with the largest holdings of TScan Therapeutics Inc. (TCRX) shares are BlackRock Health Sciences Trust II and Blackrock Funds-Health Sciences Opportunity Portfolio. Data provided on Dec 30, 2022 indicates that BlackRock Health Sciences Trust II owns about 0.86 million shares. This amounts to just over 4.48 percent of the company’s overall shares, with a $1.33 million market value. The same data shows that the other fund manager holds slightly less at 0.55 million, or about 2.89% of the stock, which is worth about $1.63 million.